Try our beta test site

A Study Evaluating Efficacy of ABT-888 in Combination With Temozolomide in Metastatic Melanoma

This study has been completed.
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) ) Identifier:
First received: December 1, 2008
Last updated: February 7, 2016
Last verified: February 2016
The purpose of this study is to evaluate the efficacy of ABT-888 in combination with temozolomide versus temozolomide alone in subjects with metastatic melanoma.

Condition Intervention Phase
Metastatic Melanoma
Skin Cancer
Drug: temozolomide
Drug: ABT-888
Other: Placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma

Resource links provided by NLM:

Further study details as provided by AbbVie:

Primary Outcome Measures:
  • Progression-Free Survival [ Time Frame: Radiographic evaluation every 2 months, clinical evaluation monthly ]

Secondary Outcome Measures:
  • Overall Survival [ Time Frame: Every 4 weeks or as needed after subject is registered as off-study, up to 18 months ]
  • 12-month Survival Rate [ Time Frame: Every cycle (28 days) ]
  • 6-month Progression Free Survival Rate [ Time Frame: Every cycle (28 days) ]
  • Time to Disease Progression [ Time Frame: Every cycle (28 days) ]

Enrollment: 346
Study Start Date: February 2009
Study Completion Date: January 2016
Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
TMZ + ABT-888 at 20 mg BID
Drug: temozolomide
150 mg/m2 temozolomide daily for 5 days every 28 days
Other Name: Temodar, Temodal
Drug: ABT-888
Either 20 mg or 40 mg BID for 7 days every 28 days
Active Comparator: 2
TMZ + ABT-888 at 40 mg BID
Drug: temozolomide
150 mg/m2 temozolomide daily for 5 days every 28 days
Other Name: Temodar, Temodal
Drug: ABT-888
Either 20 mg or 40 mg BID for 7 days every 28 days
Placebo Comparator: 3
TMZ + Placebo
Drug: temozolomide
150 mg/m2 temozolomide daily for 5 days every 28 days
Other Name: Temodar, Temodal
Other: Placebo
Placebo BID for 7 days every 28 days


Ages Eligible for Study:   18 Years to 99 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically (or cytologically) confirmed metastatic melanoma.
  • Unresectable Stage III or Stage IV metastatic melanoma.
  • Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria.
  • Subjects with no history of brain metastases demonstrated by a baseline MRI,or subjects with a history of previously treated brain metastases who have history of operable/SRS treatable brain metastases and completed surgical resection/stereotactic radiosurgery with or without adjuvant whole brain radiation at least 28 days prior to Day 1.
  • have baseline MRI that shows no evidence of active intercranial disease
  • have discontinued taking medications for symptom management of brain metastases at least 7 days prior to Day 1
  • 28 days since prior anti-cancer therapy.
  • Eastern Cooperative Oncology Group (ECOG) Performance Score of 0-1.
  • Adequate hematologic, renal and hepatic function.
  • Partial Thromboplastin Time (PTT) is <= 1.5 x upper normal limit of institution's normal range and INR < 1.5.
  • Subject's with significant fluid retention may be allowed at the discretion of the PI.
  • Life expectancy > 12 weeks.
  • Females must not be pregnant.
  • Voluntarily signed informed consent.

Exclusion Criteria:

  • Lactate Dehydrogenase (LDH) > 2 x Upper Limit of Normal (ULN).
  • Ocular malignant melanoma.
  • History of CNS metastases or leptomeningeal disease.
  • Prior treatment with Dacarbazine (DTIC) or Temozolomide (TMZ).
  • Prior DNA damaging agents or cytotoxic chemotherapy.
  • Prior Whole Brain Radiation Therapy.
  • Received an investigational agent within 28 days of study.
  • History of seizure disorder and/or taking medication for seizure disorder.
  • Active malignancy within the past 5 years, except cervical cancer in situ, in situ carcinoma of the bladder or non-melanoma carcinoma of the skin.
  • Medical condition that would cause a high risk for toxicities.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00804908

  Show 57 Study Locations
Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Study Director: Mark D McKee, MD AbbVie
  More Information

Responsible Party: AbbVie (prior sponsor, Abbott) Identifier: NCT00804908     History of Changes
Other Study ID Numbers: M10-440  2008-004941-27 
Study First Received: December 1, 2008
Last Updated: February 7, 2016

Keywords provided by AbbVie:
Metastatic Melanoma
Skin cancer

Additional relevant MeSH terms:
Skin Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Neoplasms by Site
Skin Diseases
Antineoplastic Agents, Alkylating
Alkylating Agents
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Poly(ADP-ribose) Polymerase Inhibitors
Enzyme Inhibitors processed this record on February 23, 2017